2022 CSACI annual scientific meeting book of abstracts
Bibliographic record
Abstract
Background: Allergic asthma is present in approximately 60% of adult patients with severe asthma.Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin (TSLP).This post hoc analysis evaluated the efficacy of tezepelumab with increased statistical precision in patients with severe, uncontrolled asthma and perennial aeroallergen sensitization using pooled data from the phase 2b PATHWAY and phase 3 NAVIGATOR studies.Methods: PATHWAY (NCT02054130) and NAVIGATOR (NCT03347279) were multicentre, randomized, double-blind, placebo-controlled studies with similar designs.Patients who received tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks and had a positive or negative fluorescence enzyme immunoassay test for serum-specific immunoglobulin E against at least one perennial aeroallergen were included in this analysis.The annualized asthma exacerbation rate (AAER) over 52 weeks (primary endpoint in both trials) and the annualized rate of exacerbations that required hospitalization or an emergency department (ED) visit over 52 weeks were assessed in patients grouped by perennial allergic status.Results: Overall, 1299 patients were included; 815 (63%) had perennial aeroallergen sensitization and 484 (37%) did not.Tezepelumab reduced the AAER over 52 weeks compared with placebo by 62% (95% CI: 53-70) in patients with perennial aeroallergen sensitization and by 54% (95% CI: 38-66) in those without.The annualized rate of exacerbations that required hospitalization or an ED visit was reduced with tezepelumab compared with placebo by 80% (95% CI: 61-90) in patients with perennial aeroallergen sensitization and by 74% (95% CI: 41-88) in those without.Conclusions: Tezepelumab reduced exacerbations compared with placebo, including those that required hospitalization or an ED visit, in patients with severe, uncontrolled asthma with or without perennial aeroallergen sensitization.These findings further support the benefits of tezepelumab in a broad population of patients with severe, uncontrolled asthma, including those with allergic and non-allergic asthma.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.003 | 0.002 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.642 | 0.558 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".